CD8A and cancer: Overall, our experiments uncovered no evidence that Ifnar1 KO in cancer cells led to consistently increased numbers of CD8+ T cells, enhanced expression of markers for cytotoxic capacity, or reduced exhaustion in tumor-infiltrating CD8+ T cells.